Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of cardiology working group on thrombosis

European Heart Journal

Volumn 38, Issue 19, 2017, Pages 1455-1462

  Halvorsen, Sigrun ^a   Storey, Robert F ^b   Rocca, Bianca ^c   Sibbing, Dirk ^d,e   Berg, Jurrien Ten ^f   Grove, Erik Lerkevang ^g   Weiss, Thomas W ^h   Collet, Jean Philippe ⁱ   Andreotti, Felicita ^c   Gulba, Dietrich C ^j   Lip, Gregory Y H ^k,l   Husted, Steen ^m   Vilahur, Gemma ⁿ   Morais, Joao ^o   Verheugt, Freekw A ^p   Lanas, Angel ^q   Salman, Rustam Al Shahi ^r   Steg, Philippe Gabriel ^s   Huber, Kurt ^t  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c CATHOLIC UNIVERSITY   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j St Marien Hosp Oberhausen O   (Germany)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l AALBORG UNIVERSITY   (Denmark)

^m HOLSTEBRO HOSPITAL   (Denmark)

ⁿ Institut Català de Ciències Cardiovasculars   (Spain)

^o Cardiology Department   (Portugal)

^p Emeritus of Cardiology   (Netherlands)

^q UNIVERSITY OF ZARAGOZA   (Spain)

^r UNIVERSITY OF EDINBURGH   (United Kingdom)

^s UNIVERSITÉ PARIS DESCARTES   (France)

^t ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; PRASUGREL; TICAGRELOR; VORAPAXAR; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CONSENSUS; CORONARY ARTERY DISEASE; DUAL ANTIPLATELET THERAPY; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CONSENSUS DEVELOPMENT; DRUG SUBSTITUTION; GASTROINTESTINAL HEMORRHAGE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; RISK FACTOR; STENT; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; CONSENSUS; CORONARY ARTERY DISEASE; DRUG SUBSTITUTION; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; STENTS; THROMBOSIS; VITAMIN K;

EID: 85030771070     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw454     Document Type: Article

References (84)

1. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S, CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942.
2. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KA, Wallentin L, Peters RJ, Granger CB, Joyner CD, Yusuf S. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009;30:655-661.
3. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
4. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEATPPCI): An open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-1858.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
6. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-Analysis of randomised trials. Lancet 2014;383:955-962.
7. Lopes RD, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, Magnus Ohman E, Roe MT, Peterson ED, Alexander KP. The association of in-hospital major bleeding with short-, intermediate-, and long-Term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J 2012;33:2044-2053.
8. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-782.
9. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE- 2, ACUITY, and HORIZONS-AMI trials. JACC Cardiovasc Interv 2011;4:654-664.
10. Ndrepepa G, Neumann FJ, Schulz S, Fusaro M, Cassese S, Byrne RA, Richardt G, Laugwitz KL, Kastrati A. Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheter Cardiovasc Interv 2014;83:182-189.
11. Kikkert WJ, Delewi R, Ouweneel DM, van Nes SH, Vis MM, Baan J Jr., Koch KT, Dangas GD, Mehran R, de Winter RJ, Peters RJ, Piek JJ, Tijssen JG, Henriques JP. Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: A cohort study in ST-segment elevation myocardial infarction and comprehensive meta-Analysis. JACC Cardiovasc Interv 2014;7:622-630.
12. Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, Wallentin L, Steg PG. Association of spontaneous and procedure-related bleeds with short-And longterm mortality after acute coronary syndromes: An analysis from the PLATO trial. EuroIntervention 2015;11:737-745.
13. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015;36:1264-1272.
14. Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonzalez MA, Gaglia MA Jr., Xue Z, Kaneshige K, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J 2010;159:871-875.
15. Roy P, Bonello L, Torguson R, de LA, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008;102:1614-1617.
16. Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, DeCaterina R, Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, Wallentin L, Weiss TW, Storey RF. Antithrombotic therapy in the elderly: Expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015;36:3238-3249.
17. Pollack CV Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373:511-520.
18. Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, Charbonneau H, Jaber S, Thoret S, Bosson JL, Piriou V. Non-cardiac surgery in patients with coronary stents: The RECO study. Heart 2011;97:1566-1572.
19. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-1722.
20. Stephan B, Schenk JF, Pindur G, Meiss C, Borchers H, Nemeh A, Weinrich M, Wagner B. Influence of bleeding on haemorheology and haemostasis in surgery. Clin Hemorheol Micro 2010;46:183-188.
21. Campbell CL, Steinhubl SR, Hooper WC, Jozic J, Smyth SS, Bernstein D, DeStaercke C, Syros G, Negus BH, Stuckey T, Stone GW, Mehran R, Dangas G. Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: An ACUITY trial substudy. J Thromb Thrombolysis 2011;31:139-145.
22. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Gorlinger K, Haas T, Imberger G, Jacob M, Lance M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, VanderLinden P, Wikkelso AJ, Wouters P, Wyffels P. Management of severe perioperative bleeding: guidelines from. The European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382.
23. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011;9:1705-1712.
24. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp- Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S. Reversal strategies for non-vitamin K antagonist oral anticoagulants: A critical appraisal of available evidence and recommendations for clinical management-A joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; doi: 10.1093/eurheartj/ehv676.
25. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747.
26. Pisters R, Lane DA, Nieuwlaat R, deVos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-1100.
27. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
28. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762-1771.
29. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monsegu J, Sabouret P, O'connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O, Beygui F, Silvain J, Vicaut E, Montalescot G. Investigators A. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.
30. De Caterina R, Marchioli R, Andreotti F. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013;368:871.
31. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
32. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
33. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-Term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634-1642.
34. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: The dutch stent thrombosis registry. J Am Coll Cardiol 2009;53:1399-1409.
35. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-Term follow-up. Am J Cardiol 2006;98:352-356.
36. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
37. Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S, British Society of G, British Committee for Standards in H, British Cardiovascular Intervention S. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008;57:1322-1329.
38. van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, Zwart B, Brueren BR, Koolen JJ, Dambrink JH, Van't Hof AW, Verheugt FW, ten Berg JM. Long-Term clinical outcome after a first angiographically confirmed coronary stent thrombosis: An analysis of 431 cases. Circulation 2009;119:828-834.
39. Yeo KK, Mahmud E, Armstrong EJ, Bennett WE, Shunk KA, MacGregor JS, Li Z, Low RI, Rogers JH. Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: Results from a multicenter California registry. Catheter Cardiovasc Interv 2012;79:550-556.
40. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB III, Negoita M, Liu M, dePaula JE, Mangione JA, Meireles GX, Castello HJ Jr., Nicolela EL Jr., Perin MA, Devito FS, Labrunie A, Salvadori D Jr., Gusmao M, Staico R, Costa JR Jr., deCastro JP, Abizaid AS, Bhatt DL. Investigators OT. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA 2013;310:2510-2522.
41. Navarese EP, Andreotti F, Kolodziejczak M, Schulze V, Wolff G, Dias S, Claessen B, Brouwer M, Tarantini G, Iliceto S, Brockmeyer M, Kowalewski M, Lin Y, Eikelboom J, Musumeci G, Lee L, Lip GY, Valgimigli M, Berti S, Kelm M. Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-Analysis of 42 randomised trials involving 117, 353 patients. Thromb Haemost 2015;114:933-944.
42. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC. Investigators LF. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015;373:2038-2047.
43. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Munzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10:1144-1153.
44. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen- Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-1409.
45. Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, Youn TJ, Kim HS. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: Evidence from a network meta-Analysis of 147 Trials. JACC Cardiovasc Interv 2016;9:1203-1212.
46. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol 2046;67:1145-1154.
47. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Committee TPTS, Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-1413.
48. Roe MT, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, Van't Hof AW, Montalescot G, James SK, Saucedo J, Ohman EM, Pollack CV Jr., Hochman JS, Armstrong PW, Giugliano RP, Harrington RA, Van de Werf F, Califf RM, Newby LK. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes 2012;5:205-213.
49. Chan MY, Mahaffey KW, Sun LJ, Pieper KS, White HD, Aylward PE, Ferguson JJ, Califf RM, Roe MT. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 2008;1:369-378.
50. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-Analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-2674.
51. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-Analysis. J Intern Med 2005;257:399-414.
52. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S, Investigators P. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370:1494-1503.
53. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823.
54. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med 2010;152:1-9.
55. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, Rotondano G, Hucl T, Dinis-Ribeiro M, Marmo R, Racz I, Arezzo A, Hoffmann RT, Lesur G, de Franchis R, Aabakken L, Veitch A, Radaelli F, Salgueiro P, Cardoso R, Maia L, Zullo A, Cipolletta L, Hassan C. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1-A46.
56. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:1708-1713.
57. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC. Investigators RA. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014;129:1850-1859.
58. Broderick JP, Bonomo JB, Kissela BM, Khoury JC, Moomaw CJ, Alwell K, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Kleindorfer DO. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke 2011;42:2509-2514.
59. Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-Analysis. Thromb Haemost 2015;114:819-825.
60. Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-668.
61. Yung D, Kapral MK, Asllani E, Fang J, Lee DS. Investigators of the Registry of the Canadian Stroke N. Reinitiation of anticoagulation after warfarin-Associated intracranial hemorrhage and mortality risk: The best practice for reinitiating anticoagulation therapy after intracranial bleeding (BRAIN) study. Can J Cardiol 2012;28:33-39.
62. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012;172:1484-1491.
63. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507.
64. Loffredo L, Perri L, Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-Analysis of interventional trials. Dig Liver Dis 2015;47:429-431.
65. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. Circulation 2012;126:1185-1193.
66. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van T'Hof AW, ten Berg JM, Investigators Ws. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107-1115.
67. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981-989.
68. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619-1629.
69. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-3179.
70. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634-640.
71. Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JH, Tricoci P, Lopes RD, Ohman EM, Roe MT, Harrington RA, Wallentin L. Metaanalysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc 2015;4:e001512.
72. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-2147.
73. Chandra D, Gupta A, Grover V, Kumar Gupta V. When should you restart anticoagulation in patients who suffer an intracranial bleed who also have a prosthetic valve?. Interact Cardiovasc Thorac Surg 2013;16:520-523.
74. Poli D, Antonucci E, Dentali F, Erba N, Testa S, Tiraferri E, Palareti G. Italian Federation of Anticoagulation C. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology 2014;82:1020-1026.
75. Rabinstein AA, Gupta A. Restarting anticoagulation after intracranial hemorrhage: A risky decision with no recipe. Neurology 2014;82:1016-1017.
76. Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010;41:2860-2866.
77. Poon MT, Fonville AF, Al-Shahi Salman R. Long-Term prognosis after intracerebral haemorrhage: systematic review and meta-Analysis. J Neurol Neurosurg Psychiatry 2014;85:660-667.
78. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann- Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824-836.
79. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: A nationwide cohort study. Circulation 2015;132:517-525.
80. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: A nationwide cohort study. Chest 2015;147:1651-1658.
81. Hemphill JC III, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D. American Heart Association Stroke C, Council on C, Stroke N, Council on Clinical C. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2032-2060.
82. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F., Investigators R-A. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.
83. Andreotti F, Crea F. Defining the role of left atrial appendage closure in atrial fibrillation. Rev Esp Cardiol 2013;66:79-82.
84. Patti G, Pengo V, Marcucci R, Cirillo P, Renda G, Santilli F, Calabro P, De Caterina AR, Cavallari I, Ricottini E, Parato VM, Zoppellaro G, Di Gioia G, Sedati P, Cicchitti V, Davi G, Golia E, Pariggiano I, Simeone P, Abbate R, Prisco D, Zimarino M, Sofi F, Andreotti F, De Caterina R. Working Group of Thrombosis of the Italian Society of C. The left atrial appendage: from embryology to prevention of thromboembolism. Eur Heart J 2016; doi: 10.1093/eurheartj/ehw159.